In Vitro and In Vivo Assessment of Docetaxel Formulation Developed for Esophageal Stents

Shaikh, Mohsin; Zhang, Huihui; Wang, Hongyuan; Guo, Xiu-Li; Song, Yunmei; Kanwar, Jagat R.; Garg, Sanjay

doi:10.1208/s12249-016-0501-7

Cited by 9 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reviewed articles were selected from among those extracted through a systematic review of the guidelines [5][6][7] to avoid bias from the article selection process. However, 14 articles [29][30][31][32][33][34][35][36][37][38][39][40][41][42] were added for the further exploration of topics that were not included in the guidelines. In the guidelines, the Japan Medical Library Association was entrusted with a systematic search of the literature published from January 2000 to August 2020.…”

Section: Selection Of Articlesmentioning

confidence: 99%

“…Controlled drug elution is often achieved using a drug-impregnated polymer membrane or coating that acts as a drug reservoir for sustained drug release [39]. Several approaches and drug-polymer combinations have been employed to create drug-eluting stents that deliver chemotherapy drugs, including 5-fluorouracil, paclitaxel, and docetaxel, for the treatment of esophageal cancer [40,41].…”

Section: Stent Type and Efficacymentioning

confidence: 99%

See 1 more Smart Citation

Endoscopic Stenting for Malignant Dysphagia in Patients with Esophageal Cancer

Ishihara

2023

Current Oncology

View full text Add to dashboard Cite

Malignant dysphagia is a common problem in patients with esophageal cancer. Endoscopic stenting can resolve dysphagia caused by malignant stricture; however, controversy exists regarding the use of esophageal stenting for the treatment of malignant stricture, including whether stenting or radiotherapy is superior, whether stenting before or after radiotherapy is safe, whether stenting before or after chemotherapy is safe, and whether low-radial-force stents are safer than conventional stents. Among treatment options for malignant dysphagia, stenting may have some disadvantages in terms of pain relief and the risk of adverse events compared with radiotherapy and in terms of survival compared with gastrostomy. Additionally, the risk of stent-related adverse events is significantly associated with prior radiotherapy. The risk of perforation is especially high when a radiation dose of >40 Gy is delivered to the esophagus after stenting, whereas perforation is not associated with prior chemotherapy or additional chemotherapy after stenting. Nevertheless, stenting remains an important palliative option, especially for patients with a short life expectancy and a strong desire for oral intake, because stenting can facilitate a more rapid improvement in dysphagia than radiotherapy or gastrostomy. The application of a low-radial-force stent should be considered to reduce the risk of adverse events, especially in patients with prior radiotherapy.

show abstract

Section: Selection Of Articlesmentioning

confidence: 99%

Section: Stent Type and Efficacymentioning

confidence: 99%

Endoscopic Stenting for Malignant Dysphagia in Patients with Esophageal Cancer

Ishihara

2023

Current Oncology

View full text Add to dashboard Cite

show abstract

“…Although there are few orthotopic esophageal cancer models, in the past decades there are many reports about the use of animals for the test of esophageal stents in vivo . Shaikh et al used a nude mice xenograft tumor model to test docetaxel (DTX)-loaded polyurethane formulations for stent application [84]. To test the esophageal tissue responses to nitinol stents loaded with 50% 5-FU or PTX, Guo et al used twenty-three healthy Bama minipigs to test 4 groups for stent implantation: PTX stent, 5-FU stent, blank film–covered stent, and bare stent.…”

Section: Animal Models For Esophageal Stentsmentioning

confidence: 99%

A Review of Self-Expanding Esophageal Stents for the Palliation Therapy of Inoperable Esophageal Malignancies

Kang

2019

BioMed Research International

View full text Add to dashboard Cite

Esophageal cancer is a very deadly disease, killing more than 15,000 people in the United States annually. Almost 400,000 new cases happen in the worldwide every year. More than 50% esophageal cancer patients are diagnosed at an advanced stage when they need an esophageal stent to open the blocked esophagus for feeding and drinking. Esophageal stents have evolved in stages over the years. Current clinically used stents commonly include stainless steel or nitinol self-expandable metallic stent (SEMS) and self-expandable plastic stent (SEPS). There are many choices of different types of stents and sizes, with fierce competition among manufacturers. However, current stent technology, whether uncovered, partially covered, fully covered SEMS or SEPS, has their own advantages to solve the dysphagia, stricture, and fistula problems, but they also cause some clinical complications. The ideal stent remains elusive. New 3D printing technique may bring new promising potential to manufacturing personalized esophageal stents. Drug-eluting stents could be the new avenue to do more than just pry open a stricture or cover a defect in the esophageal lumen, a possibility of proving local anticancer therapy simultaneously. Additionally, the lack of esophageal cancer animal models also hinders the progress of stent development. This paper reviews these topics for a comprehensive understanding of this field. In a conclusion, the ultimate goal of the future esophageal stent would have multifunction to treat the underlying conditions and restore esophageal function to near normal.

show abstract

“…Oesophageal cancer is often diagnosed at an advanced stage and is the sixth most common cause of cancer‐related mortality; moreover, information on the use of DES for this cancer type is meagre. A recent study investigated the use of self‐expanding metallic docetaxel stents to maintain oral alimentation and identified encouraging formulations . Wang et al developed a new approach for making nitinol stents loaded with a high dose of 5‐fluorouracil or paclitaxel with the aim of achieiving unidirectional, sustained and prolonged drug release towards the area of exposure, thus avoiding washout of the drug by oesophageal fluids and systematic administration.…”

Section: Des Targeted For Cancer Therapymentioning

confidence: 99%

“…A recent study investigated the use of self-expanding metallic docetaxel stents to maintain oral alimentation and identified encouraging formulations. 75 Wang et al 76 developed a new approach for making nitinol stents loaded with a high dose of 5-fluorouracil or paclitaxel with the aim of achieiving unidirectional, sustained and prolonged drug release towards the area of exposure, thus avoiding washout of the drug by oesophageal fluids and systematic administration. It was shown that the stent did not cause severe damage to the oesophagus walls and effectively inhibited inflammation, ulceration and granulation tissue growth, which is suggestive of hopeful treatment modality.…”

Section: Micro-rna (Mirna) Facilitated Ges Deliverymentioning

confidence: 99%

Stent‐mediated gene and drug delivery for cardiovascular disease and cancer: A brief insight

Krishnagopal

Reddy

Sen

2017

The Journal of Gene Medicine

View full text Add to dashboard Cite

This review concisely recapitulates the different existing modes of stent-mediated gene/drug delivery, their considerable advancement in clinical trials and a rationale for other merging new technologies such as nanotechnology and microRNA-based therapeutics, in addition to addressing the limitations in each of these perpetual stent platforms. Over the past decade, stent-mediated gene/drug delivery has materialized as a hopeful alternative for cardiovascular disease and cancer in contrast to routine conventional treatment modalities. Regardless of the phenomenal recent developments achieved by coronary interventions and cancer therapies that employ gene and drug-eluting stents, practical hurdles still remain a challenge. The present review highlights the limitations that each of the existing stent-based gene/drug delivery system encompasses and therefore provides a vision for the future with respect to discovering an ideal stent therapeutic platform that would circumvent all the practical hurdles witnessed with the existing technology. Further study of the improvisation of next-generation drug-eluting stents has helped to overcome the issue of restenosis to some extent. However, current stent formulations fall short of the anticipated clinically meaningful outcomes and there is an explicit need for more randomized trials aiming to further evaluate stent platforms in favour of enhanced safety and clinical value. Gene-eluting stents may hold promise in contributing new ideas for stent-based prevention of in-stent restenosis through genetic interventions by capitalizing on a wide variety of molecular targets. Therefore, the central consideration directs us toward finding an ideal stent therapeutic platform that would tackle all of the gaps in the existing technology.

show abstract

In Vitro and In Vivo Assessment of Docetaxel Formulation Developed for Esophageal Stents

Cited by 9 publications

References 22 publications

Endoscopic Stenting for Malignant Dysphagia in Patients with Esophageal Cancer

Endoscopic Stenting for Malignant Dysphagia in Patients with Esophageal Cancer

A Review of Self-Expanding Esophageal Stents for the Palliation Therapy of Inoperable Esophageal Malignancies

Stent‐mediated gene and drug delivery for cardiovascular disease and cancer: A brief insight

Contact Info

Product

Resources

About